621 related articles for article (PubMed ID: 9696028)
1. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
[TBL] [Abstract][Full Text] [Related]
2. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
3. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
[TBL] [Abstract][Full Text] [Related]
4. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
[TBL] [Abstract][Full Text] [Related]
5. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
[TBL] [Abstract][Full Text] [Related]
9. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.
Yao FY; Osorio RW; Roberts JP; Poordad FF; Briceno MN; Garcia-Kennedy R; Gish RR
Liver Transpl Surg; 1999 Nov; 5(6):491-6. PubMed ID: 10545536
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Lo CM; Liu CL; Lau GK; Chan SC; Ng IO; Fan ST
Liver Transpl; 2005 Jul; 11(7):807-813. PubMed ID: 15973721
[TBL] [Abstract][Full Text] [Related]
13. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin.
McCaughan GW; Spencer J; Koorey D; Bowden S; Bartholomeusz A; Littlejohn M; Verran D; Chui AK; Sheil AG; Jones RM; Locarnini SA; Angus PW
Liver Transpl Surg; 1999 Nov; 5(6):512-9. PubMed ID: 10545540
[TBL] [Abstract][Full Text] [Related]
15. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.
Buti M; Mas A; Prieto M; Casafont F; González A; Miras M; Herrero JI; Jardí R; Cruz de Castro E; García-Rey C
J Hepatol; 2003 Jun; 38(6):811-7. PubMed ID: 12763375
[TBL] [Abstract][Full Text] [Related]
16. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
[TBL] [Abstract][Full Text] [Related]
17. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
18. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]